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Introduction
Recently, we have witnessed the emer-
gence of the “-omics” era with proteomics,
peptidomics, degradomics, metabolomics,
fractionomics, transcriptomics, interactomics,
and so forth. However, the only “-omics”
other than genomics to become a “buzz-
word” is proteomics, a term used for studying
the proteome of an organism. With the com-
pletion of the Human Genome Project, opti-
mistic views were expressed that novel
disease-specific biomarkers will be discov-
ered through various high-throughput tech-
niques, such as microarrays and mass
spectrometry (MS). Did the current technolo-
gies deliver the goods? In the following, we
discuss briefly the current status and future
of proteomics and genomics with respect to
cancer, as it is a model disease for studying
such applications. 
Current Cancer Biomarkers
Despite tremendous progress in our under-
standing of the molecular basis of many dis-
eases, cancer continues to be a major cause of
morbidity and mortality among men and
women. There is convincing evidence that early
detection of cancer can lead to better patient
outcomes through early administration of
therapy (1). Also, better clinical outcomes can
be achieved with individualized treatments,
which are more effective in subgroups of
patients, rather than in the total patient popu-
lation. One of the best ways to diagnose cancer
early, or to predict therapeutic responses, is by
using serum or tissue biomarkers.
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Currently, a number of cancer biomarkers
are used clinically, including prostate-specific
antigen (PSA; for prostate cancer), carcinoem-
bryonic antigen (CEA; for colon, lung, and
breast cancer), the carbohydrate antigens (CA)
125 (for ovarian cancer), CA 15.3 (for breast
cancer), CA 19.9 (for gastrointestinal cancer),
α-fetoprotein (AFP; for liver and testicular
cancer), and human choriogonadotropin (hCG;
for testicular and gestational cancers). All of
these markers, despite being generally not suit-
able for population screening (because of low
diagnostic sensitivity and specificity), play a
major role in aiding diagnosis and for moni-
toring patients during therapy. Unfortunately,
these cancer biomarkers have proven to be
ineffective in detecting the early stages of dis-
ease and many suffer from low positive pre-
dictive values.
Renewed Interest in Cancer
Biomarkers
Historically, every era of cancer biomarker
discovery was associated with the emergence
of a powerful analytical technology. For
example, CEA was discovered in the 1960s
mainly as a result of the introduction of novel
and relatively sensitive immunological tech-
niques (such as radial immuno-diffusion),
which allowed for the detection of the anti-
gen in cancer tissues with high specificity
and reasonable sensitivity. CA 125 and other
CAs were developed, in the late 1970s,
because of the establishment of the mono-
clonal antibody technology. Most of these
tumor markers were discovered by using cell
lines or tumor extracts as immunogens and
then selecting specific hybridoma clones that
recognized these tumor antigens (2). With the
completion of the Human Genome Project
and the introduction of technologies that
enabled simultaneous examination of thou-
sands of proteins and genes at any given
time, such as MS and protein and DNA
arrays, a renewed interest was taken by the
proteomics and genomics community to dis-
cover novel biomarkers.
Some Proteomic and Genomic
Approaches to Biomarker
Discovery
A number of different proteomic- and
genomic-based approaches have been utilized
to date to discover disease-specific biomarkers.
Some of the approaches and strategies are
briefly described here along with an example
of how these methodologies were applied to
aid in biomarker discovery or to develop pat-
terns for early diagnosis.
Two-Dimensional Gel Electrophoresis 
and Mass Spectrometry
Two-dimensional polyacrylamide gel elec-
trophoresis, known traditionally as the gold
standard, discovery-based tool for proteo-
mics, aims to resolve and visualize protein
spots that are differentially expressed in
healthy vs diseased samples. The spots can
be excised from the gel, digested, and sub-
sequently identified via MS. Using this
methodology, Celis et al. (3) developed a
comprehensive database for bladder cancer
profiles of both transitional and squamous
cell carcinomas. Furthermore, Kageyama et al.
(4) used a differential display method of
bladder cancer vs healthy urothelial tissue
and MS to identify proteins, which are
increased in cancer tissues. Calreticulin, a
potential tumor marker, was identified in
this study as it was found in urine of
patients with bladder cancer. The authors
confirmed their data with Western blot anal-
ysis, immunoprecipitation, and immunohis-
tochemistry. They reported a sensitivity of
73% and a specificity of 86%. However, a
caveat to this technology is that the identi-
fied proteins are usually of high abundance
and the method is labor intensive. Similar
strategies have been used by many other
groups. 
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Protein Arrays
Another area of proteomic research that is
gaining popularity is the use of protein arrays
to identify novel biomarkers. Chinnaiyan and
colleagues recently published data suggesting
that autoantibody signatures may improve the
early detection of prostate cancer (5). Using a
combination of phage-display technology and
protein microarrays, they identified new
autoantibody-binding peptides derived from
prostate cancer tissue. Serum samples from 119
patients with prostate cancer and 138 control
patients were analyzed using this methodol-
ogy. Their results were impressive. A 22-phage
peptide detector had 88% specificity and 82%
sensitivity in discriminating between the two
groups. This panel of peptides seemed to per-
form better than PSA in distinguishing
between prostate cancer and the control group.
Proteomic Pattern Analysis (SELDI-TOF)
The ability to identify diseases through pro-
teomic patterns in biological fluids appeared
to be a new paradigm shift in the use of MS-
based methodologies. This approach attracted
considerable attention over the past few years.
Developed by Petricoin, Liotta, and colleagues,
this potentially revolutionary methodology
involves the use of a minute amount of unfrac-
tionated serum sample added to a “protein-
chip,” which is subsequently analyzed by
surface-enhanced laser desorption/ionization
time-of-flight (SELDI-TOF) spectrometry to
generate a proteomic signature of the serum.
These patterns reflect part of the blood pro-
teome, without knowledge of the actual iden-
tity of the proteins that make up the proteome.
The potential of proteomic pattern analysis
was first demonstrated in the diagnosis of
ovarian cancer (6). In this study, a preliminary
training set of mass spectra, generated by
SELDI-TOF, from 50 unaffected women and 50
ovarian cancer patients was obtained. Search-
ing algorithms were used to identify a pro-
teomic pattern that discriminated cancer from
noncancer. This pattern was used to classify
116 blinded serum samples. The results were
exceptional with a sensitivity of 100% at 95%
specificity. These numbers are far superior to
the sensitivities and specificities obtained with
current serologic cancer biomarkers. 
MS-Imaging (MALDI-MS)
Another proteomic pattern analysis approach
involves the use of matrix-assisted laser des-
orption/ionization (MALDI)-MS on small
amounts of fresh frozen tissue sections. In a
recent application of this methodology, termed
MS imaging, pioneered by Caprioli and col-
leagues (7), the authors profiled the protein
expression of surgically resected lung tumor
tissues (8). To detect proteomic patterns in
lung tumors, the protein expression profiles of
50 tissue samples (42 lung tumors and 8
normal lung samples) in a training cohort was
assessed. Mass spectra were obtained directly
from 1-mm regions of single frozen tissue sec-
tions. More than 1600 distinct protein species
were observed, of which 82 discriminating MS
signals were selected. A class-prediction model
was built and it was able to correctly classify
all 42 lung tumors and the 8 normal samples.
This model was further validated in an inde-
pendent blinded test cohort yielding a phe-
nomenal result of perfect classification of the
samples.
Quantitative Proteomics
Quantitative proteomics aims to measure
quantitatively the relative or absolute abun-
dance of proteins across samples. The emer-
gence of experimental protocols, such as
isotope-coded affinity tags (ICAT), iTRAQ™,
stable isotope labeling by amino acids in cell
culture (and SILAC), now allow for quantita-
tive proteomic approaches to biomarker dis-
covery. As a result, quantitative differential
analysis can be performed on an MS signal—
the end result being the identification of the
relative abundance of the molecular species
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detected in the sample. In a study by Martin
et al. (9), a cell culture model system was
used to identify secreted and cell-surface pro-
teins from neoplastic prostate epithelium
using ICAT reagents and tandem MS. Pro-
teomic analysis of the media identified more
than 600 proteins, of which 524 were quanti-
fied. This study demonstrated the feasibility
of using high-throughput quantitative pro-
teomics to identify proteins in conditioned
media. 
Genomic Approaches
Genomic microarrays represent a highly
powerful technology for genome-wide stud-
ies on gene expression, single-nucleotide
polymorphism identification, mutational
analysis, and so forth. Microarray experi-
ments are usually performed with DNA or
RNA isolated from tissues. Thus, unlike sero-
logic markers, this methodology does not
lend itself to minimally invasive diagnostics.
However, tissue biopsies can be very useful
for confirming diagnosis, for tumor sub-
classification and for predicting therapeutic
response. It was recently hypothesized that
the phenotypic differences of tumors from
different patients may be associated with
unique gene expression profiles, which can
be captured by using DNA microarrays (10).
The proof-of-principle for the cancer sub-
classification hypothesis has been provided
for various malignancies, such as breast
cancer, leukemias, and many other cancer
types (11–18). Some of the most celebrated
studies on cancer subclassification and sub-
sequent selection of therapeutic intervention
have created excitement in the media (19,20).
Other approaches, based on the same
hypothesis, used alternative technologies,
such as quantitative reverse transcriptase-
polymerase chain reaction or fluorescence in
situ hybridization to derive prognostic and
predictive information (21,22). Some of these
tests have now been submitted to the Food
and Drug Administration for approval
(Table 1).
Did Proteomic and Genomic
Methodologies Deliver the Goods?
Rapid advances in proteomic and genomic
technologies have created optimistic views
that many more cancer biomarkers will be dis-
covered through various high-throughput tech-
niques. However, these predictions have yet to
come true. Very few, if any, new serum cancer
biomarkers have been introduced at the clinic
over the last 15 yr. Organizations like the Amer-
ican Society of Clinical Oncology do not encour-
age the widespread use of tumor markers,
unless they affect patient outcome measures
(23). On the other hand, there is general agree-
ment that a combination of multiple biomark-
ers may increase the diagnostic sensitivity and
specificity of individual markers. This is partic-
ularly important in relation to the recent devel-
opment of powerful bioinformatic algorithms
(such as artificial neural networks and logistic
regression), which can interpret multiple para-
meters much more efficiently than the average
clinician (24,25).
Most of the serum proteomic pattern analy-
sis technologies (such as SELDI-TOF), although
promising, have not as yet been evaluated at
the clinic and a number of important limita-
tions have already been identified (26,27).
These limitations include the possibility of bias
stemming from artifacts related to the clinical
samples used to generate published data, the
inherent qualitative nature of MS and/or the
bioinformatic analysis applied to the raw data
(28–31). To illustrate this point, a meta-analysis
of prostate cancer proteomic data from four
articles by three different research groups was
compiled (27). The discriminatory peaks identi-
fied in the four papers using SELDI-TOF were
very different. Interestingly, two papers pub-
lished among the same group using the same
experimental data but different bioinformatic
tools yielded different discriminatory peaks.
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This raises the problem of data overfitting and
the lack of reproducibility with some of these
technologies.
In a study by Gygi and coworkers, six com-
panies were asked to analyze the same protein
extract from 10,000 human cells by liquid
chromatography-tandem MS after trypsin
digestion (32). Only 52 proteins, representing
3% of all the data, were identified by all six
participants. Furthermore, about two-thirds of
the proteins were identified by only one par-
ticipant. This exemplifies a very important
point—different MS platforms identify differ-
ent proteins in the same mixture. In addition,
it should be noted that serum is a complex
mixture and it is possible that new candidate
biomarkers have not yet been identified
because their concentrations in serum and/or
biological fluids are too low and therefore
cannot be measured or the proteins cannot 
be purified, unless specific immunological
reagents and highly sensitive enzyme-linked
immunosorbent assay methods are available.
Thus, in the initial discovery phase for novel
cancer biomarkers, a less complex sample
(elimination of high-abundant proteins) is
essential. Therefore, proteomic technologies
have yet to deliver the “goods” because they
are more difficult to find than originally
anticipated.
On the genomics side, Michiels et al. (33)
recently performed a meta-analysis of seven of
the most prominent studies on cancer progno-
sis, by using microarray-based expression 
Table 1
New and Emerging “-omic” Cancer Tests
Company Product Approval status Characteristics 
Agendia MammaPrint Pending at FDA ➣ A 70-gene expression signature 
measured on an Agilent DNA
microarray
➣ Predicts prognosis for certain 
breast cancer patients
Correlogic OvaCheck Pending at FDA ➣ Protein expression pattern 
systems analysis
➣ More than 150,000 starting data 
points are reduced to 5–10 for 
final evaluation
Exagen Breast cancer Submission for FDA ➣ Traditional FISH test, derived 
prognosis test for PMA anticipated from gene expression as well as 
by end of 2005 other data
Genomic Oncotype Dx Not an FDA-regulated ➣ A 21-gene expression assay 
health product. Launched done using RT-PCR for 
as a laboratory- prognosis in breast cancer
developed test in 
California, January 
2004
Roche Leukemia array Launch anticipated ➣ A 300-gene expression 
2006–2007 microarray test
Modified from ref. 35. 
FDA, Food and Drug Administration; FISH, fluorescent in situ hybridization; PMA, pre-market approval;  
RT-PCR, reverse transcriptase-polymerase chain reaction.
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profiling. Surprisingly, in five of the seven
studies on cancer prognosis, the original data
could not be reproduced (34). The other two
studies showed much weaker prognostic
information than the original data. The meta-
analysis also indicated that the list of genes
identified as predictors of prognosis was
highly unstable and that the molecular signa-
tures were strongly dependent on the selection
of patients in the training sets. This article sug-
gested that the results of the aforementioned
studies, as published, are highly over opti-
mistic and that they need careful validation
before conclusions can be drawn.
Where Do We Stand Today?
The emergence of the “-omics” era is an
exciting time for the scientific community. The
technologies and tools needed to decipher the
proteome of organisms and to dig deeper into
the biomarker mine are available. There is 
no doubt that, if these new technological
advances prove to be successful in identifying
cancer biomarkers for early cancer detection,
the clinical benefits are likely to be enormous.
What is not clear is which technologies will be
the most successful as it is too early to say if
we have indeed succeeded in delivering the
“goods.” We should also not forget that other
diagnostic modalities, such as imaging, may
eventually become so sensitive and specific
that the use of biomarkers for patient diagno-
sis and management may become redundant.
Have we come upon a new paradigm shift in
the use of proteomic and genomic technolo-
gies for biomarker discovery? Only meticu-
lous validation steps and time will tell.
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